-
1
-
-
76249089855
-
Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screen-ing, and treatment) to reduce future rates
-
Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, Jemal A, Schymura MJ, Lansdorp-Vogelaar I, Seeff LC, van Balle-gooijen M, Goede SL, Ries LA. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screen-ing, and treatment) to reduce future rates. Cancer 2010; 116(3): 544-573.
-
(2010)
Cancer
, vol.116
, Issue.3
, pp. 544-573
-
-
Edwards, B.K.1
Ward, E.2
Kohler, B.A.3
Eheman, C.4
Zauber, A.G.5
Anderson, R.N.6
Jemal, A.7
Schymura, M.J.8
Lansdorp-Vogelaar, I.9
Seeff, L.C.10
van Balle-gooijen, M.11
Goede, S.L.12
Ries, L.A.13
-
2
-
-
79952232216
-
Global cancer statistics
-
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90.
-
(2011)
CA Cancer J Clin
, vol.61
, Issue.2
, pp. 69-90
-
-
Jemal, A.1
Bray, F.2
Center, M.M.3
Ferlay, J.4
Ward, E.5
Forman, D.6
-
3
-
-
0027297154
-
A phase II study of methotrexate, vinblastine, doxorubi-cin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma
-
Moore MJ, Iscoe N, Tannock IF.A phase II study of methotrexate, vinblastine, doxorubi-cin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma. J Urol 1993; 150(4): 1131-1134.
-
(1993)
J Urol
, vol.150
, Issue.4
, pp. 1131-1134
-
-
Moore, M.J.1
Iscoe, N.2
Tannock, I.F.3
-
4
-
-
29144519778
-
Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: Long-term follow-up of a 3-week regimen
-
Adamo V, Magno C, Spitaleri G, Garipoli C, Maisano C, Alafaci E, Adamo B, Rossello R, Scandurra G, Scimone A. Phase II study of gemcitabine and cisplatin in patients with advanced or metastatic bladder cancer: long-term follow-up of a 3-week regimen. Oncology 2005; 69(5): 391-398.
-
(2005)
Oncology
, vol.69
, Issue.5
, pp. 391-398
-
-
Adamo, V.1
Magno, C.2
Spitaleri, G.3
Garipoli, C.4
Maisano, C.5
Alafaci, E.6
Adamo, B.7
Rossello, R.8
Scandurra, G.9
Scimone, A.10
-
5
-
-
17444437833
-
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer
-
Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18(9): 1921-1927.
-
(2000)
J Clin Oncol
, vol.18
, Issue.9
, pp. 1921-1927
-
-
Kaufman, D.1
Raghavan, D.2
Carducci, M.3
Levine, E.G.4
Murphy, B.5
Aisner, J.6
Kuzel, T.7
Nicol, S.8
Oh, W.9
Stadler, W.10
-
6
-
-
0032858246
-
Gem-citabine plus cisplatin, an active regimen in advanced urothelial cancer: A phase II trial of the National Cancer Institute of Canada Clini-cal Trials Group
-
Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L. Gem-citabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clini-cal Trials Group. J Clin Oncol 1999; 17(9): 2876-2881.
-
(1999)
J Clin Oncol
, vol.17
, Issue.9
, pp. 2876-2881
-
-
Moore, M.J.1
Winquist, E.W.2
Murray, N.3
Tannock, I.F.4
Huan, S.5
Bennett, K.6
Walsh, W.7
Seymour, L.8
-
7
-
-
0033857218
-
Gemcitabine and cisplatin versus meth-otrexate, vinblastine, doxorubicin, and cis-platin in advanced or metastatic bladder can-cer: Results of a large, randomized, multina-tional, multicenter, phase III study
-
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, San-chez Rovira P, Wersall P, Cleall SP, Roychowd-hury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus meth-otrexate, vinblastine, doxorubicin, and cis-platin in advanced or metastatic bladder can-cer: results of a large, randomized, multina-tional, multicenter, phase III study. J Clin Oncol 2000; 18(17): 3068-3077.
-
(2000)
J Clin Oncol
, vol.18
, Issue.17
, pp. 3068-3077
-
-
von der Maase, H.1
Hansen, S.W.2
Roberts, J.T.3
Dogliotti, L.4
Oliver, T.5
Moore, M.J.6
Bodrogi, I.7
Albers, P.8
Knuth, A.9
Lippert, C.M.10
Kerbrat, P.11
San-Chez, R.P.12
Wersall, P.13
Cleall, S.P.14
Roychowd-Hury, D.F.15
Tomlin, I.16
Visseren-Grul, C.M.17
Conte, P.F.18
-
8
-
-
0035986528
-
Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer
-
Stadler WM, Hayden A, von der Maase H, Roy-chowdhury D, Dogliotti L, Seymour L, Kauf-mann D, Moore M. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 2002; 7(4): 153-157.
-
(2002)
Urol Oncol
, vol.7
, Issue.4
, pp. 153-157
-
-
Stadler, W.M.1
Hayden, A.2
von der Maase, H.3
Roy-Chowdhury, D.4
Dogliotti, L.5
Seymour, L.6
Kauf-Mann, D.7
Moore, M.8
-
9
-
-
36549023828
-
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study (abstract #LBA 5030)
-
Bellmunt J, von der Maase H, Mead GM, Heyer J, Houede N, Paz-Ares LG, Winquist E, Lauf-man LR, de Wit R, Sylvester R. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study (abstract #LBA 5030). J Clin Oncol 2007; 25: 965s.
-
(2007)
J Clin Oncol
, vol.965 s
, pp. 25
-
-
Bellmunt, J.1
von der Maase, H.2
Mead, G.M.3
Heyer, J.4
Houede, N.5
Paz-Ares, L.G.6
Winquist, E.7
Lauf-Man, L.R.8
de Wit, R.9
Sylvester, R.10
-
10
-
-
1542329005
-
The erbB family: Targets for therapeutic development against cancer and therapeutic strategies using monoclonal anti-bodies and tyrosine kinase inhibitors
-
Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal anti-bodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433-457.
-
(2004)
Annu Rev Med
, vol.55
, pp. 433-457
-
-
Rowinsky, E.K.1
-
11
-
-
0034730323
-
Receptor tyrosine kinases: Specific outcomes from general signals
-
Simon MA. Receptor tyrosine kinases: specific outcomes from general signals. Cell 2000; 103: 13-15.
-
(2000)
Cell
, vol.103
, pp. 13-15
-
-
Simon, M.A.1
-
12
-
-
0031827950
-
The erbB/HER type1 tyrosine kinase receptor family
-
Walker RA. The erbB/HER type1 tyrosine kinase receptor family. J Pathol 1998; 185: 234-35.
-
(1998)
J Pathol
, vol.185
, pp. 234-235
-
-
Walker, R.A.1
-
13
-
-
0034644539
-
Cell signaling by receptor tyro-sine kinases
-
Schlessinger J. Cell signaling by receptor tyro-sine kinases. Cell 2000; 103: 211-225.
-
(2000)
Cell
, vol.103
, pp. 211-225
-
-
Schlessinger, J.1
-
14
-
-
0032791110
-
Take your partners, please: Signal diversification by the erbB family of receptor tyrosine kinases
-
Daly RJ. Take your partners, please: signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors 1999; 16: 255-263.
-
(1999)
Growth Factors
, vol.16
, pp. 255-263
-
-
Daly, R.J.1
-
15
-
-
55849126233
-
Signal integration: A framework for understanding the efficacy of therapeutics targeting the hu- man EGFR family
-
Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the hu- man EGFR family J Clin Invest 2008; 118(11): 3574-3581.
-
(2008)
J Clin Invest
, vol.118
, Issue.11
, pp. 3574-3581
-
-
Shepard, H.M.1
Brdlik, C.M.2
Schreiber, H.3
-
16
-
-
0023595325
-
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene
-
Velu TJ, Beguinot L, Vass WC, Willingham MC, Merlino GT, Pastan I, Lowy DR. Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science 1987; 238: 1408-1410.
-
(1987)
Science
, vol.238
, pp. 1408-1410
-
-
Velu, T.J.1
Beguinot, L.2
Vass, W.C.3
Willingham, M.C.4
Merlino, G.T.5
Pastan, I.6
Lowy, D.R.7
-
17
-
-
0024355092
-
Autocrine interaction between TGF-a and the EGF - re-ceptor: Quantitative requirements for induc-tion of the malignant phenotype
-
Di Marco E, Pierce JH, Fleming TP, Kraus MH, Molloy CJ, Aaronson SA, Di Fiore PP. Autocrine interaction between TGF-a and the EGF - re-ceptor: quantitative requirements for induc-tion of the malignant phenotype. Oncogene 1989; 4: 831-838.
-
(1989)
Oncogene
, vol.4
, pp. 831-838
-
-
di Marco, E.1
Pierce, J.H.2
Fleming, T.P.3
Kraus, M.H.4
Molloy, C.J.5
Aaronson, S.A.6
di Fiore, P.P.7
-
18
-
-
44149087535
-
ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer
-
Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008; 13: 215-223.
-
(2008)
J Mammary Gland Biol Neoplasia
, vol.13
, pp. 215-223
-
-
Stern, D.F.1
-
19
-
-
33744912774
-
Controlled activation of ErbB1/ErbB2 heterodimers pro-mote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: Implications for progression of ErbB2-overexpressing tumors
-
Zhan L, Xiang B, Muthuswamy SK. Controlled activation of ErbB1/ErbB2 heterodimers pro-mote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors. Cancer Res 2006; 66: 5201-5208.
-
(2006)
Cancer Res
, vol.66
, pp. 5201-5208
-
-
Zhan, L.1
Xiang, B.2
Muthuswamy, S.K.3
-
20
-
-
49649103585
-
The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation
-
Najy AJ, Day KC, Day ML. The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem 2008; 283(26): 18393-18401.
-
(2008)
J Biol Chem
, vol.283
, Issue.26
, pp. 18393-18401
-
-
Najy, A.J.1
Day, K.C.2
Day, M.L.3
-
21
-
-
34247863773
-
The neuregulin-I/ErbB signaling system in development and disease
-
Britsch S. The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007; 190: 1-65.
-
(2007)
Adv Anat Embryol Cell Biol
, vol.190
, pp. 1-65
-
-
Britsch, S.1
-
23
-
-
37849046940
-
ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis
-
Revillion F, Lhotellier V, Hornez L, Bonneterre J, Peyrat JP. ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis. Ann Oncol 2008; 19: 73-80.
-
(2008)
Ann Oncol
, vol.19
, pp. 73-80
-
-
Revillion, F.1
Lhotellier, V.2
Hornez, L.3
Bonneterre, J.4
Peyrat, J.P.5
-
24
-
-
0031452314
-
Clinicopa-thological significance of epidermal growth factor and its receptor in human pancreatic cancer
-
Uegaki K, Nio Y, Inoue Y, Minari Y, Sato Y, Song MM, Dong M, Tamura K. Clinicopa-thological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 1997; 17: 3841-3847.
-
(1997)
Anticancer Res
, vol.17
, pp. 3841-3847
-
-
Uegaki, K.1
Nio, Y.2
Inoue, Y.3
Minari, Y.4
Sato, Y.5
Song, M.M.6
Dong, M.7
Tamura, K.8
-
25
-
-
77956629278
-
Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis
-
Neto AS, Tobias-Machado M, Wroclawski ML, Fonseca FL, Teixeira GK, Amarante RD, Wro-clawski ER, Del Giglio A. Her-2/neu expression in prostate adenocarcinoma: a systematic review and meta-analysis. J Urol 2010; 184(3): 842-850.
-
(2010)
J Urol
, vol.184
, Issue.3
, pp. 842-850
-
-
Neto, A.S.1
Tobias-Machado, M.2
Wroclawski, M.L.3
Fonseca, F.L.4
Teixeira, G.K.5
Amarante, R.D.6
Wro-Clawski, E.R.7
del Giglio, A.8
-
26
-
-
0027238684
-
Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate can-cer
-
Sadasivan R, Morgan R, Jennings S, Aus-tenfeld M, Van Veldhuizen P, Stephens R, Noble M. Overexpression of Her-2/neu may be an indicator of poor prognosis in prostate can-cer. J Urol 1993; 150(1): 126-131.
-
(1993)
J Urol
, vol.150
, Issue.1
, pp. 126-131
-
-
Sadasivan, R.1
Morgan, R.2
Jennings, S.3
Aus-Tenfeld, M.4
van Veldhuizen, P.5
Stephens, R.6
Noble, M.7
-
27
-
-
7144227965
-
Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials
-
Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997; 8: 1997-1206.
-
(1997)
Ann Oncol
, vol.8
, pp. 1997-1206
-
-
Voldborg, B.R.1
Damstrup, L.2
Spang-Thomsen, M.3
Poulsen, H.S.4
-
28
-
-
0032731892
-
Tumor invasion: Role of growth factor - induced cell motility
-
Wells A. Tumor invasion: role of growth factor - induced cell motility. Adv Cancer Res 2000; 78: 31-101.
-
(2000)
Adv Cancer Res
, vol.78
, pp. 31-101
-
-
Wells, A.1
-
29
-
-
0032549570
-
Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts
-
Verbeek BS, Adriaansen-Slot SS, Vroom TM, Beckers T, Rijksen G. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998; 425: 145-150.
-
(1998)
FEBS Lett
, vol.425
, pp. 145-150
-
-
Verbeek, B.S.1
Adriaansen-Slot, S.S.2
Vroom, T.M.3
Beckers, T.4
Rijksen, G.5
-
30
-
-
0036651519
-
EGFR antisense treatment of human HNSCC cell lines down - regulates VEGF ex-pression and endothelial cell migration
-
Riedel F, Gotte K, Li M, Hormann K, Grandis JR. EGFR antisense treatment of human HNSCC cell lines down - regulates VEGF ex-pression and endothelial cell migration. Int J Oncol 2002; 21: 11-16.
-
(2002)
Int J Oncol
, vol.21
, pp. 11-16
-
-
Riedel, F.1
Gotte, K.2
Li, M.3
Hormann, K.4
Grandis, J.R.5
-
31
-
-
0033650082
-
Cell biology of lymphatics metasta-sis. The potential role of c-erbB oncogene signaling
-
Eccles SA. Cell biology of lymphatics metasta-sis. The potential role of c-erbB oncogene signaling. Recent Results Cancer Res 2000; 157: 41-54.
-
(2000)
Recent Results Cancer Res
, vol.157
, pp. 41-54
-
-
Eccles, S.A.1
-
33
-
-
0030980531
-
Significance of uri-nary epidermal growth factor and its receptor expression in human bladder cancer
-
Chow NH, Liu HS, Lee EI, Chang CJ, Chan SH, Cheng HL, Tzai TS, Lin JS. Significance of uri-nary epidermal growth factor and its receptor expression in human bladder cancer. Antican-cer Res 1997; 17: 1293-1296.
-
(1997)
Antican-cer Res
, vol.17
, pp. 1293-1296
-
-
Chow, N.H.1
Liu, H.S.2
Lee, E.I.3
Chang, C.J.4
Chan, S.H.5
Cheng, H.L.6
Tzai, T.S.7
Lin, J.S.8
-
34
-
-
0028115726
-
Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multi-variate survival analysis
-
Nguyen PL, Swanson PE, Jaszcz W, Aeppli DM, Zhang G, Singleton TP, Ward S, Dykoski D, Harvey J, Niehans GA. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multi-variate survival analysis. Am J Clin Pathol 1994; 101: 166-176.
-
(1994)
Am J Clin Pathol
, vol.101
, pp. 166-176
-
-
Nguyen, P.L.1
Swanson, P.E.2
Jaszcz, W.3
Aeppli, D.M.4
Zhang, G.5
Singleton, T.P.6
Ward, S.7
Dykoski, D.8
Harvey, J.9
Niehans, G.A.10
-
35
-
-
84920241849
-
Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tu-mours
-
Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR, Harris AL. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tu-mours. Lancet 1985; 1: 366-368.
-
(1985)
Lancet
, vol.1
, pp. 366-368
-
-
Neal, D.E.1
Marsh, C.2
Bennett, M.K.3
Abel, P.D.4
Hall, R.R.5
Sainsbury, J.R.6
Harris, A.L.7
-
36
-
-
0025237455
-
The epidermal growth factor receptor and the prognosis of bladder cancer
-
Neal DE, Sharples L, Smith K, Fennelly J, Hall RR, Harris AL. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer 1990; 65: 1619-1625.
-
(1990)
Cancer
, vol.65
, pp. 1619-1625
-
-
Neal, D.E.1
Sharples, L.2
Smith, K.3
Fennelly, J.4
Hall, R.R.5
Harris, A.L.6
-
37
-
-
0025232322
-
Clinical implications of the ex-pression of epidermal growth factor receptors in human transitional cell carcinoma
-
Messing EM. Clinical implications of the ex-pression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res 1990; 50: 2530-2537.
-
(1990)
Cancer Res
, vol.50
, pp. 2530-2537
-
-
Messing, E.M.1
-
38
-
-
0032513506
-
Expression of epidermal growth factor receptor in urinary bladder can-cer metastases
-
Bue P, Wester K, Sjöström A, Holmberg A, Nilsson S, Carlsson J, Westlin JE, Busch C, Malmström PU. Expression of epidermal growth factor receptor in urinary bladder can-cer metastases. Int J Cancer 1998; 76: 189-193.
-
(1998)
Int J Cancer
, vol.76
, pp. 189-193
-
-
Bue, P.1
Wester, K.2
Sjöström, A.3
Holmberg, A.4
Nilsson, S.5
Carlsson, J.6
Westlin, J.E.7
Busch, C.8
Malmström, P.U.9
-
39
-
-
0028302276
-
Expression of epi-dermal growth factor receptor in bladder can-cer as related to established prognostic fac-tors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
-
Lipponen P, Eskelinen M. Expression of epi-dermal growth factor receptor in bladder can-cer as related to established prognostic fac-tors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 1994; 69: 1120-1125.
-
(1994)
Br J Cancer
, vol.69
, pp. 1120-1125
-
-
Lipponen, P.1
Eskelinen, M.2
-
40
-
-
34248365114
-
Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor recep-tor/ErbB1 expression in bladder cancer and their relation to clinical outcome
-
Kramer C, Klasmeyer K, Bojar H, Schulz WA, Ackermann R, Grimm MO. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor recep-tor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer 2007; 109: 2016-2024.
-
(2007)
Cancer
, vol.109
, pp. 2016-2024
-
-
Kramer, C.1
Klasmeyer, K.2
Bojar, H.3
Schulz, W.A.4
Ackermann, R.5
Grimm, M.O.6
-
41
-
-
0028939310
-
Long-term outcome related to epidermal growth factor receptor status in bladder can-cer
-
Mellon K, Wright C, Kelly P, Horne CH, Neal DE. Long-term outcome related to epidermal growth factor receptor status in bladder can-cer. J Urol 1995; 153: 919-925.
-
(1995)
J Urol
, vol.153
, pp. 919-925
-
-
Mellon, K.1
Wright, C.2
Kelly, P.3
Horne, C.H.4
Neal, D.E.5
-
42
-
-
33745272244
-
The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: A study in bladder cancer patients
-
Memon AA, Sorensen BS, Meldgaard P, Fokdal L, Thykjaer T, Nexo E. The relation between survival and expression of HER1 and HER2 depends on the expression of HER3 and HER4: a study in bladder cancer patients. Br J Cancer 2006; 94: 1703-1709.
-
(2006)
Br J Cancer
, vol.94
, pp. 1703-1709
-
-
Memon, A.A.1
Sorensen, B.S.2
Meldgaard, P.3
Fokdal, L.4
Thykjaer, T.5
Nexo, E.6
-
43
-
-
38349061851
-
Growth factors and re-ceptors as prognostic markers in urothelial carcinoma
-
Black PC, Dinney CP. Growth factors and re-ceptors as prognostic markers in urothelial carcinoma. Curr Urol Rep 2008; 9(1): 55-61.
-
(2008)
Curr Urol Rep
, vol.9
, Issue.1
, pp. 55-61
-
-
Black, P.C.1
Dinney, C.P.2
-
44
-
-
36749029619
-
Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer
-
Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L, Wei C, Baggerly K, Bar-Eli M, McConkey D, Czerniak B, Dinney CP. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008; 179(1): 353-358.
-
(2008)
J Urol
, vol.179
, Issue.1
, pp. 353-358
-
-
Kassouf, W.1
Black, P.C.2
Tuziak, T.3
Bondaruk, J.4
Lee, S.5
Brown, G.A.6
Adam, L.7
Wei, C.8
Baggerly, K.9
Bar-Eli, M.10
McConkey, D.11
Czerniak, B.12
Dinney, C.P.13
-
45
-
-
13244251056
-
Differential radio-sensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines
-
Maddineni SB, Sangar VK, Hendry JH, Margison GP, Clarke NW. Differential radio-sensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines. Br J Cancer 2005; 92: 125-130.
-
(2005)
Br J Cancer
, vol.92
, pp. 125-130
-
-
Maddineni, S.B.1
Sangar, V.K.2
Hendry, J.H.3
Margison, G.P.4
Clarke, N.W.5
-
46
-
-
33845476894
-
Inhibition of the epidermal growth factor re-ceptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly in-creases apoptosis
-
Munk M, Memon AA, Nexo E, Sorensen BS. Inhibition of the epidermal growth factor re-ceptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly in-creases apoptosis. BJU Int 2007; 99(1): 196-201.
-
(2007)
BJU Int
, vol.99
, Issue.1
, pp. 196-201
-
-
Munk, M.1
Memon, A.A.2
Nexo, E.3
Sorensen, B.S.4
-
47
-
-
67149143257
-
Dual epidermal growth factor receptor and vascular endothe-lial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner
-
Flaig TW, Su LJ, McCoach C, Li Y, Raben D, Varella-Garcia M, Bemis LT. Dual epidermal growth factor receptor and vascular endothe-lial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. BJU Int 2009; 103(12): 1729-1737.
-
(2009)
BJU Int
, vol.103
, Issue.12
, pp. 1729-1737
-
-
Flaig, T.W.1
Su, L.J.2
McCoach, C.3
Li, Y.4
Raben, D.5
Varella-Garcia, M.6
Bemis, L.T.7
-
48
-
-
77957337150
-
VEGFR and EGFR inhibition increases epithelial cellular charac-teristics and chemotherapy sensitivity in mes-enchymal bladder cancer cells
-
Li Y, Yang X, Su LJ, Flaig TW. VEGFR and EGFR inhibition increases epithelial cellular charac-teristics and chemotherapy sensitivity in mes-enchymal bladder cancer cells. Oncol Rep 2010; 24(4): 1019-1028.
-
(2010)
Oncol Rep
, vol.24
, Issue.4
, pp. 1019-1028
-
-
Li, Y.1
Yang, X.2
Su, L.J.3
Flaig, T.W.4
-
49
-
-
69349087756
-
miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
-
Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009; 15(16): 5060-5072.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.16
, pp. 5060-5072
-
-
Adam, L.1
Zhong, M.2
Choi, W.3
Qi, W.4
Nicoloso, M.5
Arora, A.6
Calin, G.7
Wang, H.8
Siefker-Radtke, A.9
McConkey, D.10
Bar-Eli, M.11
Dinney, C.12
-
50
-
-
70749137263
-
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response
-
Bhuvaneswari R, Gan YY, Soo KC, Olivo M. Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response. Mol Cancer 2009; 8: 94.
-
(2009)
Mol Cancer
, vol.8
, pp. 94
-
-
Bhuvaneswari, R.1
Gan, Y.Y.2
Soo, K.C.3
Olivo, M.4
-
51
-
-
40949091867
-
Sensitivity to epider-mal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells
-
Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theo-dorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ, Dinney CP. Sensitivity to epider-mal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008; 14(5): 1478-1486.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.5
, pp. 1478-1486
-
-
Black, P.C.1
Brown, G.A.2
Inamoto, T.3
Shrader, M.4
Arora, A.5
Siefker-Radtke, A.O.6
Adam, L.7
Theo-Dorescu, D.8
Wu, X.9
Munsell, M.F.10
Bar-Eli, M.11
McConkey, D.J.12
Dinney, C.P.13
-
52
-
-
75149171017
-
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carci-noma of the urothelium
-
Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, Goodwin JW, Twardowski PW, Atkins JN, Kakhil SR, Lange MK, Mansukhani M, Craw-ford ED. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carci-noma of the urothelium. BJU Int. 2010; 105(3): 317-321.
-
(2010)
BJU Int
, vol.105
, Issue.3
, pp. 317-321
-
-
Petrylak, D.P.1
Tangen, C.M.2
van Veldhuizen Jr., P.J.3
Goodwin, J.W.4
Twardowski, P.W.5
Atkins, J.N.6
Kakhil, S.R.7
Lange, M.K.8
Mansukhani, M.9
Craw-Ford, E.D.10
-
53
-
-
80051739850
-
Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in pre-viously treated metastatic urothelial cancer
-
abstr 243
-
Wong Y, Litwin S, Plimack ER, Vaughn DJ, Song W, Cohen SM, Lee JW, Dabrow MB, Tut-tle H, Hudes GR. Effect of EGFR inhibition with cetuximab on the efficacy of paclitaxel in pre-viously treated metastatic urothelial cancer. J Clin Oncol 29: 2011 (suppl 7; abstr 243).
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 7
-
-
Wong, Y.1
Litwin, S.2
Plimack, E.R.3
Vaughn, D.J.4
Song, W.5
Cohen, S.M.6
Lee, J.W.7
Dabrow, M.B.8
Tut-Tle, H.9
Hudes, G.R.10
-
54
-
-
0026486874
-
An immunohis-tologic evaluation of C-erb-B-2 gene product in patients with urinary bladder carcinoma
-
Sato K, Moriyama M, Mori S, Saito M, Wata-nuki T, Terada K, Okuhara E, Akiyama T, Toyo-shima K, Yamamoto T, Kato T. An immunohis-tologic evaluation of C-erb-B-2 gene product in patients with urinary bladder carcinoma. Can-cer 1992; 70: 2493-2498.
-
(1992)
Can-cer
, vol.70
, pp. 2493-2498
-
-
Sato, K.1
Moriyama, M.2
Mori, S.3
Saito, M.4
Wata-Nuki, T.5
Terada, K.6
Okuhara, E.7
Akiyama, T.8
Toyo-Shima, K.9
Yamamoto, T.10
Kato, T.11
-
55
-
-
0029655413
-
C-Erb-B2 in bladder cancer: Mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value
-
Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-Erb-B2 in bladder cancer: mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155(1): 321-326.
-
(1996)
J Urol
, vol.155
, Issue.1
, pp. 321-326
-
-
Mellon, J.K.1
Lunec, J.2
Wright, C.3
Horne, C.H.4
Kelly, P.5
Neal, D.E.6
-
56
-
-
0036331813
-
HER-2: A possible target for therapy of metastatic urinary bladder carci-noma
-
Wester K, Sjöström A, de la Torre M, Carlsson J, Malmström PU. HER-2: a possible target for therapy of metastatic urinary bladder carci-noma. Acta Oncol 2002; 41: 282-288.
-
(2002)
Acta Oncol
, vol.41
, pp. 282-288
-
-
Wester, K.1
Sjöström, A.2
de la Torre, M.3
Carlsson, J.4
Malmström, P.U.5
-
57
-
-
0036721561
-
Does HER2/ neu expression provide prognostic information in patients with ad-vanced urothelial carcinoma?
-
Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y, Meyers FJ, DeVere-White R. Does HER2/ neu expression provide prognostic information in patients with ad-vanced urothelial carcinoma? Cancer 2002; 95: 1009-1015.
-
(2002)
Cancer
, vol.95
, pp. 1009-1015
-
-
Gandour-Edwards, R.1
Lara Jr., P.N.2
Folkins, A.K.3
Lasalle, J.M.4
Beckett, L.5
Li, Y.6
Meyers, F.J.7
Devere-White, R.8
-
58
-
-
0034782994
-
Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci-noma of the urinary bladder
-
Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carci-noma of the urinary bladder. Clin Cancer Res 2001; 7: 1957-1962.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1957-1962
-
-
Chow, N.H.1
Chan, S.H.2
Tzai, T.S.3
Ho, C.L.4
Liu, H.S.5
-
59
-
-
0034890387
-
Her-2/neu overex-pression in muscle-invasive urothelial carci-noma of the bladder: Prognostic significance and comparative analysis in primary and me-tastatic tumors
-
Jimenez RE, Hussain M, Bianco FJ Jr, Vai-shampayan U, Tabazcka P, Sakr WA, Pontes JE, Wood DP Jr, Grignon DJ. Her-2/neu overex-pression in muscle-invasive urothelial carci-noma of the bladder: prognostic significance and comparative analysis in primary and me-tastatic tumors. Clin Cancer Res 2001; 7(8): 2440-2447.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.8
, pp. 2440-2447
-
-
Jimenez, R.E.1
Hussain, M.2
Bianco Jr., F.J.3
Vai-Shampayan, U.4
Tabazcka, P.5
Sakr, W.A.6
Pontes, J.E.7
Wood Jr., D.P.8
Grignon, D.J.9
-
60
-
-
77951471947
-
Assessing Her-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: Results in 1005 patients
-
Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P, Vieillefond A. Assessing Her-2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 2010; 21(4): 815-819.
-
(2010)
Ann Oncol
, vol.21
, Issue.4
, pp. 815-819
-
-
Laé, M.1
Couturier, J.2
Oudard, S.3
Radvanyi, F.4
Beuzeboc, P.5
Vieillefond, A.6
-
61
-
-
21044446131
-
Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based che-motherapy: A report from the Radiation Ther-apy Oncology Group
-
Chakravarti A, Winter K, Wu CL, Kaufman D, Hammond E, Parliament M, Tester W, Hagan M, Grignon D, Heney N, Pollack A, Sandler H, Shipley W. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based che-motherapy: a report from the Radiation Ther-apy Oncology Group. Int J Radiat Oncol Biol Phys 2005; 62(2): 309-317.
-
(2005)
Int J Radiat Oncol Biol Phys
, vol.62
, Issue.2
, pp. 309-317
-
-
Chakravarti, A.1
Winter, K.2
Wu, C.L.3
Kaufman, D.4
Hammond, E.5
Parliament, M.6
Tester, W.7
Hagan, M.8
Grignon, D.9
Heney, N.10
Pollack, A.11
Sandler, H.12
Shipley, W.13
-
62
-
-
0026321254
-
Use of inmunohisto-chemically demonstrated c-erb B-2 oncopro-tein expression as a prognostic factor in tran-sitional cell carcinoma of the urinary bladder
-
Lipponen P, Eskelinen M, Syrjänen S, Terva-hauta A, Syrjänen K. Use of inmunohisto-chemically demonstrated c-erb B-2 oncopro-tein expression as a prognostic factor in tran-sitional cell carcinoma of the urinary bladder. Eur Urol 1991; 20: 238-242.
-
(1991)
Eur Urol
, vol.20
, pp. 238-242
-
-
Lipponen, P.1
Eskelinen, M.2
Syrjänen, S.3
Terva-Hauta, A.4
Syrjänen, K.5
-
63
-
-
0028883362
-
Prognostic value of the amplification of c-erb-B2 in bladder carcinoma
-
Lönn U, Lönn S, Friberg S, Nilsson B, Silfverswärd C, Stenkvist B. Prognostic value of the amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1995; 1: 1189-1194.
-
(1995)
Clin Cancer Res
, vol.1
, pp. 1189-1194
-
-
Lönn, U.1
Lönn, S.2
Friberg, S.3
Nilsson, B.4
Silfverswärd, C.5
Stenkvist, B.6
-
64
-
-
0032519575
-
Invasion of the bladder by transitional cell carcinoma: Its relation to his-tologic grade and expression of p53, MIB-1, c-Erb-B2, epidermal growth factor receptor and bcl-2
-
Vollmer RT, Humphrey PA, Swanson PE, Wick MR, Hudson ML. Invasion of the bladder by transitional cell carcinoma: its relation to his-tologic grade and expression of p53, MIB-1, c-Erb-B2, epidermal growth factor receptor and bcl-2. Cancer 1998; 82: 715-723
-
(1998)
Cancer
, vol.82
, pp. 715-723
-
-
Vollmer, R.T.1
Humphrey, P.A.2
Swanson, P.E.3
Wick, M.R.4
Hudson, M.L.5
-
65
-
-
0029655413
-
C-erbB-2 in bladder cancer: Mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value
-
Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: mo-lecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996; 155(1): 321-326.
-
(1996)
J Urol
, vol.155
, Issue.1
, pp. 321-326
-
-
Mellon, J.K.1
Lunec, J.2
Wright, C.3
Horne, C.H.4
Kelly, P.5
Neal, D.E.6
-
66
-
-
37649024111
-
Tissue microar-ray based analysis of prognostic markers in invasive bladder cancer: Much effort to no avail?
-
Liedberg F, Anderson H, Chebil G, Gudjonsson S, Höglund M, Lindgren D, Lundberg LM, Löv-gren K, Fernö M, Månsson W. Tissue microar-ray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008; 26(1): 17-24.
-
(2008)
Urol Oncol
, vol.26
, Issue.1
, pp. 17-24
-
-
Liedberg, F.1
Anderson, H.2
Chebil, G.3
Gudjonsson, S.4
Höglund, M.5
Lindgren, D.6
Lundberg, L.M.7
Löv-Gren, K.8
Fernö, M.9
Månsson, W.10
-
67
-
-
22344437801
-
ErbB receptor expression patterns in hu-man bladder cancer
-
Rajjayabun PH, Keegan PE, Lunec J, Mellon JK. ErbB receptor expression patterns in hu-man bladder cancer. Urology 2005; 66(1): 196-200.
-
(2005)
Urology
, vol.66
, Issue.1
, pp. 196-200
-
-
Rajjayabun, P.H.1
Keegan, P.E.2
Lunec, J.3
Mellon, J.K.4
-
68
-
-
33947720526
-
Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncopro-tein in the prognosis for the clinical course of bladder cancer
-
Masliukova EA, Pozharisski KM, Karelin MI, Startsev VIu, Ten VP. Role of Ki-67, mutated gene-suppressor p53 and HER-2neu oncopro-tein in the prognosis for the clinical course of bladder cancer. Vopr Onkol 2006; 52(6): 643-648.
-
(2006)
Vopr Onkol
, vol.52
, Issue.6
, pp. 643-648
-
-
Masliukova, E.A.1
Pozharisski, K.M.2
Karelin, M.I.3
Startsev, V.4
Ten, V.P.5
-
69
-
-
52649176386
-
Prognostic signifi-cance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy
-
Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN, Kumar R. Prognostic signifi-cance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008; 40(2): 321-327.
-
(2008)
Int Urol Nephrol
, vol.40
, Issue.2
, pp. 321-327
-
-
Kolla, S.B.1
Seth, A.2
Singh, M.K.3
Gupta, N.P.4
Hemal, A.K.5
Dogra, P.N.6
Kumar, R.7
-
70
-
-
0037058715
-
HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic implications
-
Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T, Sayk F, Feller AC, Böhle A. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002; 102(5): 514-518.
-
(2002)
Int J Cancer
, vol.102
, Issue.5
, pp. 514-518
-
-
Krüger, S.1
Weitsch, G.2
Büttner, H.3
Matthiensen, A.4
Böhmer, T.5
Marquardt, T.6
Sayk, F.7
Feller, A.C.8
Böhle, A.9
-
71
-
-
35348900030
-
Does HER2 immu-noreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
-
Tsai YS, Tzai TS, Chow NH. Does HER2 immu-noreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy? Urol Int 2007; 79(3): 210-216.
-
(2007)
Urol Int
, vol.79
, Issue.3
, pp. 210-216
-
-
Tsai, Y.S.1
Tzai, T.S.2
Chow, N.H.3
-
72
-
-
70350049933
-
Prognostic impact of HER2/neu pro-tein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of al-most 20 years' research
-
Skagias L, Politi E, Karameris A, Sambaziotis D, Archondakis A, Vasou O, Ntinis A, Michalopoulou F, Moreas I, Koutselini H, Pat-souris E. Prognostic impact of HER2/neu pro-tein in urothelial bladder cancer. Survival analysis of 80 cases and an overview of al-most 20 years' research. J BUON 2009; 14(3): 457-462.
-
(2009)
J BUON
, vol.14
, Issue.3
, pp. 457-462
-
-
Skagias, L.1
Politi, E.2
Karameris, A.3
Sambaziotis, D.4
Archondakis, A.5
Vasou, O.6
Ntinis, A.7
Michalopoulou, F.8
Moreas, I.9
Koutselini, H.10
Pat-Souris, E.11
-
73
-
-
77957135510
-
Human epi-dermal growth factor receptor 2 expression status provides independent prognostic infor-mation in patients with urothelial carcinoma of the urinary bladder
-
Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI, Lotan Y. Human epi-dermal growth factor receptor 2 expression status provides independent prognostic infor-mation in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010; 106(8): 1216-1222.
-
(2010)
BJU Int
, vol.106
, Issue.8
, pp. 1216-1222
-
-
Bolenz, C.1
Shariat, S.F.2
Karakiewicz, P.I.3
Ashfaq, R.4
Ho, R.5
Sagalowsky, A.I.6
Lotan, Y.7
-
74
-
-
77953053340
-
Clinical significance of Her2/neu overexpression in urothelial carcino-mas
-
Alexa A, Baderca F, Zǎhoi DE, Lighezan R, Izvernariu D, Raica M. Clinical significance of Her2/neu overexpression in urothelial carcino-mas. Rom J Morphol Embryol 2010; 51(2): 277-282.
-
(2010)
Rom J Morphol Embryol
, vol.51
, Issue.2
, pp. 277-282
-
-
Alexa, A.1
Baderca, F.2
Zǎhoi, D.E.3
Lighezan, R.4
Izvernariu, D.5
Raica, M.6
-
75
-
-
58549118062
-
No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas
-
Caner V, Turk NS, Duzcan F, Tufan NL, Kelten EC, Zencir S, Dodurga Y, Bagci H, Duzcan SE. No strong association between HER-2/neu protein overexpression and gene amplification in high-grade invasive urothelial carcinomas. Pathol Oncol Res 2008; 14(3): 261-266.
-
(2008)
Pathol Oncol Res
, vol.14
, Issue.3
, pp. 261-266
-
-
Caner, V.1
Turk, N.S.2
Duzcan, F.3
Tufan, N.L.4
Kelten, E.C.5
Zencir, S.6
Dodurga, Y.7
Bagci, H.8
Duzcan, S.E.9
-
76
-
-
65849287224
-
Role of polysomy 17 in transitional cell carcinoma of the bladder: Immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17
-
Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17. Int J Surg Pathol 2009; 17(3): 198-205.
-
(2009)
Int J Surg Pathol
, vol.17
, Issue.3
, pp. 198-205
-
-
Simonetti, S.1
Russo, R.2
Ciancia, G.3
Altieri, V.4
de Rosa, G.5
Insabato, L.6
-
77
-
-
48649083362
-
HER2 overexpression and amplification in urothelial carcinoma of the bladder is associ-ated with MYC coamplification in a subset of cases
-
Hansel DE, Swain E, Dreicer R, Tubbs RR. HER2 overexpression and amplification in urothelial carcinoma of the bladder is associ-ated with MYC coamplification in a subset of cases. Am J Clin Pathol 2008; 130(2): 274-281.
-
(2008)
Am J Clin Pathol
, vol.130
, Issue.2
, pp. 274-281
-
-
Hansel, D.E.1
Swain, E.2
Dreicer, R.3
Tubbs, R.R.4
-
78
-
-
67349136325
-
Immunohistochemical com-parison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the uri-nary tract and typical invasive urothelial carci-noma with retraction artifact
-
Sangoi AR, Higgins JP, Rouse RV, Schneider AG, McKenney JK. Immunohistochemical com-parison of MUC1, CA125, and Her2Neu in invasive micropapillary carcinoma of the uri-nary tract and typical invasive urothelial carci-noma with retraction artifact. Mod Pathol 2009; 22(5): 660-667.
-
(2009)
Mod Pathol
, vol.22
, Issue.5
, pp. 660-667
-
-
Sangoi, A.R.1
Higgins, J.P.2
Rouse, R.V.3
Schneider, A.G.4
McKenney, J.K.5
-
79
-
-
77955079033
-
HER-2/AKT expression in upper urinary tract urothelial carcinoma: Prognostic implications
-
Izquierdo L, Truan D, Mengual L, Mallofré C, Alcaraz A. HER-2/AKT expression in upper urinary tract urothelial carcinoma: prognostic implications. Anticancer Res 2010; 30(6): 2439-2445.
-
(2010)
Anticancer Res
, vol.30
, Issue.6
, pp. 2439-2445
-
-
Izquierdo, L.1
Truan, D.2
Mengual, L.3
Mallofré, C.4
Alcaraz, A.5
-
80
-
-
27144451261
-
Trastu-zumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: Report on six patients
-
discussion 775-778
-
Peyromaure M, Scotté F, Amsellem-Ouazana D, Vieillefond A, Oudard S, Beuzeboc P. Trastu-zumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol 2005; 48(5): 771-775; discussion 775-778.
-
(2005)
Eur Urol
, vol.48
, Issue.5
, pp. 771-775
-
-
Peyromaure, M.1
Scotté, F.2
Amsellem-Ouazana, D.3
Vieillefond, A.4
Oudard, S.5
Beuzeboc, P.6
-
81
-
-
34250218955
-
Trastuzumab, paclitaxel, car-boplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: Results of a mul-ticenter phase II National Cancer Institute trial
-
Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U, Lara PN Jr, Chatta GS, Nanus DM, Glode LM, Trump DL, Chen H, Smith DC. Trastuzumab, paclitaxel, car-boplatin and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a mul-ticenter phase II National Cancer Institute trial. J Clin Oncol 2007; 25: 2218-2224.
-
(2007)
J Clin Oncol
, vol.25
, pp. 2218-2224
-
-
Hussain, M.H.1
Macvicar, G.R.2
Petrylak, D.P.3
Dunn, R.L.4
Vaishampayan, U.5
Lara Jr., P.N.6
Chatta, G.S.7
Nanus, D.M.8
Glode, L.M.9
Trump, D.L.10
Chen, H.11
Smith, D.C.12
-
82
-
-
33847022350
-
Combined treatment of bladder cancer cell lines with lapatinib and varying chemo-therapy regimens-evidence of scheduled-dependent synergy
-
McHugh LA, Kriajevska M, Mellon JK, GriYths TR. Combined treatment of bladder cancer cell lines with lapatinib and varying chemo-therapy regimens-evidence of scheduled-dependent synergy. Urology 2007;69(2):390-394.
-
(2007)
Urology
, vol.69
, Issue.2
, pp. 390-394
-
-
McHugh, L.A.1
Kriajevska, M.2
Mellon, J.K.3
Griyths, T.R.4
-
83
-
-
67649417899
-
Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of com-bination chemotherapy in bladder cancer cells
-
McHugh LA, Sayan AE, Mejlvang J, Griffiths TR, Sun Y, Manson MM, Tulchinsky E, Mellon JK, Kriajevska M. Lapatinib, a dual inhibitor of ErbB-1/-2 receptors, enhances effects of com-bination chemotherapy in bladder cancer cells. Int J Oncol 2009; 34(4): 1155-1163.
-
(2009)
Int J Oncol
, vol.34
, Issue.4
, pp. 1155-1163
-
-
McHugh, L.A.1
Sayan, A.E.2
Mejlvang, J.3
Griffiths, T.R.4
Sun, Y.5
Manson, M.M.6
Tulchinsky, E.7
Mellon, J.K.8
Kriajevska, M.9
-
84
-
-
54249157033
-
Lapatinib (Tykerb, GW572016) re-verses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2
-
Dai CL, Tiwari AK, Wu CP, Su XD, Wang SR, Liu DG, Ashby CR Jr, Huang Y, Robey RW, Liang YJ, Chen LM, Shi CJ, Ambudkar SV, Chen ZS, Fu LW. Lapatinib (Tykerb, GW572016) re-verses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Can-cer Res 2008; 68(19): 7905-7914.
-
(2008)
Can-cer Res
, vol.68
, Issue.19
, pp. 7905-7914
-
-
Dai, C.L.1
Tiwari, A.K.2
Wu, C.P.3
Su, X.D.4
Wang, S.R.5
Liu, D.G.6
Ashby Jr., C.R.7
Huang, Y.8
Robey, R.W.9
Liang, Y.J.10
Chen, L.M.11
Shi, C.J.12
Ambudkar, S.V.13
Chen, Z.S.14
Fu, L.W.15
-
85
-
-
67649579849
-
A single-arm, multicen-ter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
-
Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F, El-Hariry IA. A single-arm, multicen-ter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115(13): 2881-2890.
-
(2009)
Cancer
, vol.115
, Issue.13
, pp. 2881-2890
-
-
Wülfing, C.1
Machiels, J.P.2
Richel, D.J.3
Grimm, M.O.4
Treiber, U.5
de Groot, M.R.6
Beuzeboc, P.7
Parikh, R.8
Pétavy, F.9
El-Hariry, I.A.10
-
86
-
-
70350738476
-
Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer
-
Havaleshko DM, Smith SC, Cho H, Cheon S, Owens CR, Lee JK, Liotta LA, Espina V, Wulfkuhle JD, Petricoin EF, Theodorescu D. Comparison of global versus epidermal growth factor receptor pathway profiling for prediction of lapatinib sensitivity in bladder cancer. Neo-plasia 2009; 11(11): 1185-1193.
-
(2009)
Neo-plasia
, vol.11
, Issue.11
, pp. 1185-1193
-
-
Havaleshko, D.M.1
Smith, S.C.2
Cho, H.3
Cheon, S.4
Owens, C.R.5
Lee, J.K.6
Liotta, L.A.7
Espina, V.8
Wulfkuhle, J.D.9
Petricoin, E.F.10
Theodorescu, D.11
-
87
-
-
0029741999
-
Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tu-mours
-
DiGiovanna MP, Carter D, Flynn SD, Stern DF. Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tu-mours. Br J Cancer 1996; 74: 802-806.
-
(1996)
Br J Cancer
, vol.74
, pp. 802-806
-
-
Digiovanna, M.P.1
Carter, D.2
Flynn, S.D.3
Stern, D.F.4
-
88
-
-
33644750227
-
Phosphorylation of tyrosine 1248-ERBB2 measured by chemilumines-cence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients
-
Cicenas J, Urban P, Kung W, Vuaroqueaux V, Labuhn M, Wight E, Eppenberger U, Eppenber-ger-Castori S. Phosphorylation of tyrosine 1248-ERBB2 measured by chemilumines-cence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer 2006; 42: 636-645.
-
(2006)
Eur J Cancer
, vol.42
, pp. 636-645
-
-
Cicenas, J.1
Urban, P.2
Kung, W.3
Vuaroqueaux, V.4
Labuhn, M.5
Wight, E.6
Eppenberger, U.7
Eppenber-ger-Castori, S.8
-
89
-
-
31844447885
-
Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastu-zumab-based therapy in patients with metas-tatic breast cancer
-
Hudelist G, Köstler WJ, Czerwenka K, Kubista E, Attems J, Müller R, Gschwantler-Kaulich D, Manavi M, Huber I, Hoschützky H, Zielinski CC, Singer CF. Her-2/neu and EGFR tyrosine kinase activation predict the efficacy of trastu-zumab-based therapy in patients with metas-tatic breast cancer. Int J Cancer 2006; 118: 1126-1134.
-
(2006)
Int J Cancer
, vol.118
, pp. 1126-1134
-
-
Hudelist, G.1
Köstler, W.J.2
Czerwenka, K.3
Kubista, E.4
Attems, J.5
Müller, R.6
Gschwantler-Kaulich, D.7
Manavi, M.8
Huber, I.9
Hoschützky, H.10
Zielinski, C.C.11
Singer, C.F.12
-
90
-
-
51049091694
-
Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
-
Zhang D, Pal A, Bornmann WG, Yamasaki F, Esteva FJ, Hortobagyi GN, Bartholomeusz C, Ueno NT. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008; 7: 1846-1850.
-
(2008)
Mol Cancer Ther
, vol.7
, pp. 1846-1850
-
-
Zhang, D.1
Pal, A.2
Bornmann, W.G.3
Yamasaki, F.4
Esteva, F.J.5
Hortobagyi, G.N.6
Bartholomeusz, C.7
Ueno, N.T.8
-
91
-
-
20244388653
-
Study of the biologic effects of lapatinib, a reversible inhibi-tor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in pa-tients with advanced malignancies
-
Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S. Study of the biologic effects of lapatinib, a reversible inhibi-tor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in pa-tients with advanced malignancies. J Clin On-col 2005; 23: 2502-2512.
-
(2005)
J Clin On-col
, vol.23
, pp. 2502-2512
-
-
Spector, N.L.1
Xia, W.2
Burris 3rd., H.3
Hurwitz, H.4
Dees, E.C.5
Dowlati, A.6
O'Neil, B.7
Overmoyer, B.8
Marcom, P.K.9
Blackwell, K.L.10
Smith, D.A.11
Koch, K.M.12
Stead, A.13
Mangum, S.14
Ellis, M.J.15
Liu, L.16
Man, A.K.17
Bremer, T.M.18
Harris, J.19
Bacus, S.20
more..
-
92
-
-
67649365635
-
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
-
Karamouzis MV, Konstantinopoulos PA, Pa-pavassiliou AG. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors. Lancet Oncol 2009; 10: 709-717.
-
(2009)
Lancet Oncol
, vol.10
, pp. 709-717
-
-
Karamouzis, M.V.1
Konstantinopoulos, P.A.2
Pa-Pavassiliou, A.G.3
-
93
-
-
0034698096
-
Transactivation of the EGF receptor mediates IGF-1-stimulated shc phos-phorylation and ERK1/2 activation in COS-7 cells
-
Roudabush FL, Pierce KL, Maudsley S, Khan KD, Luttrell LM. Transactivation of the EGF receptor mediates IGF-1-stimulated shc phos-phorylation and ERK1/2 activation in COS-7 cells. J Biol Chem 2000; 275(29): 22583-22589.
-
(2000)
J Biol Chem
, vol.275
, Issue.29
, pp. 22583-22589
-
-
Roudabush, F.L.1
Pierce, K.L.2
Maudsley, S.3
Khan, K.D.4
Luttrell, L.M.5
-
94
-
-
58149250928
-
Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression
-
Cabodi S, Morello V, Masi A, Cicchi R, Broggio C, Distefano P, Brunelli E, Silengo L, Pavone F, Arcangeli A, Turco E, Tarone G, Moro L, De-filippi P. Convergence of integrins and EGF receptor signaling via PI3K/Akt/FoxO pathway in early gene Egr-1 expression. J Cell Physiol 2009; 218(2): 294-303.
-
(2009)
J Cell Physiol
, vol.218
, Issue.2
, pp. 294-303
-
-
Cabodi, S.1
Morello, V.2
Masi, A.3
Cicchi, R.4
Broggio, C.5
Distefano, P.6
Brunelli, E.7
Silengo, L.8
Pavone, F.9
Arcangeli, A.10
Turco, E.11
Tarone, G.12
Moro, L.13
De-Filippi, P.14
-
95
-
-
30044446209
-
Prognos-tic markers for bladder cancer: International Consensus Panel on bladder tumor markers
-
Habuchi T, Marberger M, Droller MJ, Hem-street GP 3rd, Grossman HB, Schalken JA, Schmitz-Dräger BJ, Murphy WM, Bono AV, Goebell P, Getzenberg RH, Hautmann SH, Messing E, Fradet Y, Lokeshwar VB. Prognos-tic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005; 66(6 Suppl. 1): 64-74.
-
(2005)
Urology
, vol.66
, Issue.6 SUPPL. 1
, pp. 64-74
-
-
Habuchi, T.1
Marberger, M.2
Droller, M.J.3
Hem-Street 3rd., G.P.4
Grossman, H.B.5
Schalken, J.A.6
Schmitz-Dräger, B.J.7
Murphy, W.M.8
Bono, A.V.9
Goebell, P.10
Getzenberg, R.H.11
Hautmann, S.H.12
Messing, E.13
Fradet, Y.14
Lokeshwar, V.B.15
|